Summit Therapeutics Announces Phase III Trial HARMONi-2 Meets Primary Endpoint Of Progression-Free Survival For Ivonescimab In Advanced NSCLC With PD-L1 Expression

Merck & Co., Inc. -2.09% Pre
Summit Therapeutic -3.70% Pre

Merck & Co., Inc.

MRK

125.44

125.44

-2.09%

0.00% Pre

Summit Therapeutic

SMMT

9.12

9.12

-3.70%

0.00% Pre

  • Unprecedented: Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in Randomized Phase III Clinical Trial in NSCLC
  • Monotherapy Ivonescimab Achieved Clinically Meaningful PFS Benefit in HARMONi-2 Trial Conducted by Akeso
  • PFS Improvement Was Observed Broadly in Patients Across Subgroups, including PD-L1 Low and PD-L1 High Expressing Tumors, Squamous and Non-Squamous Histologies
  • Full Data Set to be Presented at an Upcoming Major Medical Conference Planned for Later This Year
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via